Telix Pharmaceuticals (ASX:TLX) said the Brazilian Health Regulatory Agency approved its prostate cancer imaging agent Illuccix, according to a Tuesday Australian bourse filing.
The marketing authorization was granted to Telix's partner R2PHARMA, a unit of Grupo GSH. Telix provided Grupo GSH with an exclusive license to manufacture, distribute, and market Illuccix in Brazil, the filing said.
Telix and R2PHARMA will set up a joint venture, Telix Innovations Brazil, to commercialize and distribute Telix's therapeutic and diagnostic radiopharmaceutical products in Brazil. Telix Innovations Brazil will hold the exclusive license to commercialize and distribute Illuccix as well as future product candidates.
Illuccix, after radiolabeling with gallium-68, is a radioactive diagnostic agent used in conjunction with positron emission tomography to detect prostate-specific membrane antigen-positive lesions in men with prostate cancer.
It is already commercially available in Australia, Canada, New Zealand, as well as the US, and has recently been approved in the UK.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。